GlassScriptPhysician profile
Anne Julia Thomson
NPI 1619964764
$6,827.60
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,559 · 2022: $2,920 · 2023: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $742.30 | 2021-2023 | Austedo, Austedo Xr, Ajovy |
| Genzyme Corporation | $542.98 | 2021-2023 | |
| Abbvie INC. | $532.33 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $420.27 | 2022 | |
| Amgen INC. | $391.02 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $366.90 | 2021 | |
| Ucb, INC. | $342.37 | 2021-2023 | Briviact |
| Sk Life Science, INC. | $309.15 | 2021-2023 | |
| Genentech USA, INC. | $305.14 | 2021-2023 | Enspryng, Ocrevus |
| Lilly USA, LLC | $293.43 | 2021-2023 | Reyvow, Emgality |
| Amneal Pharmaceuticals LLC | $272.02 | 2021-2023 | Lyvispah |
| Celgene Corporation | $222.73 | 2021-2022 | |
| Lundbeck LLC | $186.49 | 2021-2023 | Vyepti |
| Argenx US, INC. | $174.70 | 2022-2023 | Vyvgart |
| Alexion Pharmaceuticals, INC. | $164.62 | 2021-2023 | Ultomiris |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Thomson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.